SPOR and xEVMPD Stakeholder Engagement Webinars : Referentials Management Service (RMS), Online, from 03/10/2023 to 03/10/2023

SPOR and xEVMPD Stakeholder Engagement Webinars : Service Desk for SPOR and XEVMPD, Online, from 10/10/2023 to 10/10/2023

SPOR and xEVMPD Stakeholder Engagement Webinars : Substance Management Service (SMS), Online, from 05/10/2023 to 05/10/2023

List of centrally authorised products requiring a notification of a change for update of annexes

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 October 2023

Industry Standing Group meetings

Human medicines European public assessment report (EPAR): Emselex, darifenacin hydrobromide, Urinary Incontinence, Urge;Urinary Bladder, Overactive, Date of authorisation: 22/10/2004, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Pemetrexed Accord, pemetrexed, Carcinoma, Non-Small-Cell Lung;Mesothelioma, Date of authorisation: 18/01/2016, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), dinutuximab beta, Neuroblastoma, Date of authorisation: 08/05/2017, Revision: 16, Status: Authorised

Multistakeholder workshop on Patient Registries, European Medicines Agency, Amsterdam, the Netherlands, from 12/02/2024 to 13/02/2024